- Home
- BRNS vs KLRS Comparison
BRNS vs KLRS Comparison
Compare BRNS & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- KLRS
- Stock Information
- Founded
- BRNS 2016
- KLRS 2019
- Country
- BRNS United Kingdom
- KLRS United States
- Employees
- BRNS N/A
- KLRS N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRNS Health Care
- KLRS Health Care
- Exchange
- BRNS Nasdaq
- KLRS Nasdaq
- Market Cap
- BRNS 55.9M
- KLRS 46.0M
- IPO Year
- BRNS 2021
- KLRS N/A
- Fundamental
- Price
- BRNS $0.75
- KLRS $6.30
- Analyst Decision
- BRNS Strong Buy
- KLRS Strong Buy
- Analyst Count
- BRNS 1
- KLRS 3
- Target Price
- BRNS $4.00
- KLRS $21.50
- AVG Volume (30 Days)
- BRNS 111.8K
- KLRS 100.6K
- Earning Date
- BRNS 11-07-2025
- KLRS 11-12-2025
- Dividend Yield
- BRNS N/A
- KLRS N/A
- EPS Growth
- BRNS N/A
- KLRS N/A
- EPS
- BRNS N/A
- KLRS N/A
- Revenue
- BRNS N/A
- KLRS N/A
- Revenue This Year
- BRNS N/A
- KLRS N/A
- Revenue Next Year
- BRNS N/A
- KLRS N/A
- P/E Ratio
- BRNS N/A
- KLRS N/A
- Revenue Growth
- BRNS 1766.46
- KLRS N/A
- 52 Week Low
- BRNS $0.64
- KLRS $2.14
- 52 Week High
- BRNS $2.92
- KLRS $15.63
- Technical
- Relative Strength Index (RSI)
- BRNS 24.92
- KLRS 67.64
- Support Level
- BRNS $0.75
- KLRS $4.73
- Resistance Level
- BRNS $0.81
- KLRS $5.24
- Average True Range (ATR)
- BRNS 0.11
- KLRS 0.49
- MACD
- BRNS -0.04
- KLRS 0.14
- Stochastic Oscillator
- BRNS 0.06
- KLRS 97.98
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.